MARKET

DTIL

DTIL

Precision BioSciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.14
+0.13
+1.85%
Closed 16:42 06/01 EDT
OPEN
6.96
PREV CLOSE
7.01
HIGH
7.54
LOW
6.76
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
23.67
52 WEEK LOW
4.600
MARKET CAP
367.10M
P/E (TTM)
-2.7244
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DTIL stock price target is 19.67 with a high estimate of 25.00 and a low estimate of 7.00.

EPS

DTIL News

More
Precision BioSciences to Present at Upcoming Investor Conferences
GlobeNewswire · 6d ago
These Analysts Just Made A Decent Downgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) EPS Forecasts
Simply Wall St. · 05/18 11:34
Precision BioSciences: Q1 Earnings Insights
Benzinga · 05/15 13:52
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Zacks · 05/15 13:15
Precision BioSciences: Q1 Earnings Insights
Shares of Precision BioSciences (NASDAQ:DTIL) rose 8.2% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 73.87% year over year to ($0.52), which were in line with the estimate of ($0.52).
Benzinga · 05/15 12:52
Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update
GlobeNewswire · 05/15 12:00
Precision BioSciences Q1 EPS $(0.520), Inline, Sales $7.000M Beat $4.260M Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.520) per share which met the analyst consensus estimate. This is a 73.87 percent increase over losses of $(1.990) per share from the same period last
Benzinga · 05/15 11:09
Earnings Scheduled For May 15, 2020
Companies Reporting Before The Bell V.F. Corporation (NYSE: VFC) is projected to report quarterly earnings at $0.13 per share on revenue of $2.31 billion.
Benzinga · 05/15 09:06

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About DTIL

Precision BioSciences, Inc. is a genome editing company. The Company is engaged in providing genome engineering technology. The Company’s ARCUS genome editing technology enables the production of specific nucleases that can insert, remove and modify deoxyribonucleic acid (DNA) at any location in a genome. The Company is also engaged in developing genome editing-based product leads for human therapeutic, agricultural and biologics manufacturing applications. The Company’s four product candidates in its CAR T cell development pipeline are PBCAR0191, PBCAR20A, PBCAR269A and PBCAR371A. The Company’s ARCUS platform designed to treat human diseases and create healthy and sustainable food and agricultural solutions. It also developing product candidates in three areas to overcome the limitations of other genome editing technologies: allogeneic CAR T immunotherapy, in vivo gene correction, and food.
More

Webull offers kinds of Precision BioSciences Inc stock information, including NASDAQ:DTIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTIL stock news, and many more online research tools to help you make informed decisions.